Armin Ghobadi
About
Armin Ghobadi is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine.
According to data from OpenAlex, Armin Ghobadi has authored 152 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Oncology, 44 papers in Hematology and 33 papers in Pathology and Forensic Medicine. Recurrent topics in Armin Ghobadi's work include CAR-T cell therapy research (98 papers), Lymphoma Diagnosis and Treatment (33 papers) and Acute Lymphoblastic Leukemia research (20 papers). Armin Ghobadi is often cited by papers focused on CAR-T cell therapy research (98 papers), Lymphoma Diagnosis and Treatment (33 papers) and Acute Lymphoblastic Leukemia research (20 papers). Armin Ghobadi collaborates with scholars based in United States, France and Australia. Armin Ghobadi's co-authors include Frederick L. Locke, Sattva S. Neelapu, William Y. Go, Adrian Bot, John M. Rossi, Allen Xue, Nancy L. Bartlett, Tanya Siddiqi, Caron A. Jacobson and John F. DiPersio and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Armin Ghobadi
142 papers receiving 2.0k citations
Hit Papers
Peers
Armin Ghobadi
Cecilia C.S. Yeung United States
Sherry Adkins United States
Elena Mead United States
Maksim Mamonkin United States
Colette Chaney United States
Nicholas Tschernia United States
D. Stroncek United States
Elise A. Chong United States
Haruko Tashiro Japan
Citations per year, relative to Armin Ghobadi Armin Ghobadi (= 1×)
peers
Cecilia C.S. Yeung
Countries citing papers authored by Armin Ghobadi
Since
Specialization
Citations
This map shows the geographic impact of Armin Ghobadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Ghobadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Ghobadi more than expected).
Fields of papers citing papers by Armin Ghobadi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Armin Ghobadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Ghobadi. The network helps show where Armin Ghobadi may publish in the future.
Co-authorship network of co-authors of Armin Ghobadi
This figure shows the co-authorship network connecting the top 25 collaborators of Armin Ghobadi. A scholar is included among the top collaborators of Armin Ghobadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armin Ghobadi. Armin Ghobadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ghobadi, Armin, Robert A. Baiocchi, Sridhar Chaganti, et al.. (2025). Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus–Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy. Transplantation and Cellular Therapy. 31(2). S506–S507.
2.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990.
3.
Ghobadi, Armin, Ibrahim Aldoss, Shannon L. Maude, et al.. (2024). Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL). Transplantation and Cellular Therapy. 30(2). S14–S15.
4.
Bhaskar, Shakthi, Babatunde Adedokun, Olalekan O. Oluwole, et al.. (2024). Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report. Blood. 144(Supplement 1). 527–527.
5.
Ghobadi, Armin, Joseph P. McGuirk, Paul Shaughnessy, et al.. (2024). CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 144(Supplement 1). 4829–4829.
6.
Oluwole, Olalekan O., Armin Ghobadi, Ryan D. Cassaday, et al.. (2024). Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.. Journal of Clinical Oncology. 42(16_suppl). 6531–6531.
7.
Ghobadi, Armin, Michael P. Rettig, Amanda F. Cashen, et al.. (2023). Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Advances. 8(3). 513–522.
8.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2023). Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study. Transplantation and Cellular Therapy. 29(2). S371–S372.
9.
Abboud, Ramzi, Feng Gao, Michael P. Rettig, et al.. (2022). A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(3). S298–S299.
10.
Salter, Amber, Marcus P. Watkins, Daniel R. Ludwig, et al.. (2022). Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Cancers. 14(12). 2932–2932.
11.
Goldsmith, Scott, et al.. (2022). Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. Transplantation and Cellular Therapy. 28(11). 727–736.
12.
Ghobadi, Armin, Rowena Delos Santos, Joel D. Schilling, et al.. (2020). CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. American Journal of Transplantation. 21(2). 809–814.
13.
Pasquini, Marcelo C., Frederick L. Locke, Alex F. Herrera, et al.. (2019). Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood. 134(Supplement_1). 764–764.
14.
King, Justin, Mark A. Fiala, Scott Goldsmith, et al.. (2019). Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood. 134(Supplement_1). 5701–5701.
15.
Fiala, Mark A., Tanya M. Wildes, Mark A. Schroeder, et al.. (2018). Disparities in Healthcare Resource Utilization for Multiple Myeloma. Blood. 132(Supplement 1). 4793–4793.
16.
Ali, Alaa M., Feng Gao, Geoffrey L. Uy, et al.. (2017). Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen. Cancer Medicine. 6(12). 2814–2821.
17.
Schroeder, Mark A., Mark A. Fiala, Armin Ghobadi, et al.. (2017). Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy. Blood. 130. 4335–4335.
18.
Wei, Andrew H., Josep‐María Ribera, Giovanni Martinelli, et al.. (2017). Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study. Blood. 130. 2556–2556.
19.
Fiala, Mark A., Tanya M. Wildes, Gunjan L. Shah, et al.. (2017). A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma. Blood. 130. 3108–3108.
20.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2016). A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. Blood. 128(22). 998–998.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cecilia C.S. Yeung Breakdown of academic impact, for papers by Sherry Adkins Breakdown of academic impact, for papers by Elena Mead Breakdown of academic impact, for papers by Maksim Mamonkin Breakdown of academic impact, for papers by Colette Chaney Breakdown of academic impact, for papers by Nicholas Tschernia Breakdown of academic impact, for papers by D. Stroncek Breakdown of academic impact, for papers by Elise A. Chong Breakdown of academic impact, for papers by Haruko Tashiro